載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$3.194
−US$0.086 · -2.62%
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
一般交易時段
US$3.194
−US$0.086 · -2.62%
盤中時間採用ET。市場資料可能有所延遲。
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
日內區間
目前US$3.194
52週區間
目前US$3.194
盤中時間採用ET。市場資料可能有所延遲。
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
日內區間
目前US$3.194
52週區間
目前US$3.194
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 9460萬 USD | 1.39億 USD | 1.4億 USD | 1.11億 USD | 1.34億 USD |
| 銷貨成本 | 2970.39萬 USD | 3128.92萬 USD | 1782.51萬 USD | 1043.26萬 USD | 1660.19萬 USD |
| 毛利 | 6487.1萬 USD | 1.07億 USD | 1.22億 USD | 1億 USD | 1.17億 USD |
| 研究與開發 | 652.68萬 USD | 1231.08萬 USD | 1642.79萬 USD | 2252.56萬 USD | 994.22萬 USD |
| 銷售、一般及管理費用 | 312.82萬 USD | 2513.61萬 USD | 2204.3萬 USD | 3511.72萬 USD | 1803.36萬 USD |
| 營業費用 | 4116.89萬 USD | 3744.68萬 USD | 3847.1萬 USD | 5764.29萬 USD | 2797.58萬 USD |
| 利息收入 | 667.99萬 USD | — | — | — | — |
| 折舊和攤銷 | 56.26萬 USD | 53.84萬 USD | 53.83萬 USD | 51.76萬 USD | 52.24萬 USD |
| 營業利益 | 2370萬 USD | 6998.33萬 USD | 8362.12萬 USD | 4270.02萬 USD | 8909.28萬 USD |
| 淨利 | 2330萬 USD | 5921.42萬 USD | 6806.88萬 USD | 3390.48萬 USD | 6945.08萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV432.3萬0.01%308.51億 USD0.25%US$120.28+0.54%
Vanguard Morningstar Total Stock Market ETFVTI378.73萬0.00%2.3兆 USD0.03%US$381.78-0.04%
iShares Russell 2000 ETFIWM376.61萬0.00%787.4億 USD0.19%US$278.49-0.16%
Vanguard Extended Market ETFVXF154.61萬0.00%954億 USD0.05%US$234.21-0.34%
Dimensional - US Targeted Value ETFDFAT141.03萬0.00%301.22億 USD0.33%US$67.685+0.62%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV116.72萬0.00%268.09億 USD0.33%US$38.115+0.43%
Dimensional - US Small Cap ETFDFAS103.18萬0.00%338.69億 USD0.31%US$78.42+0.09%
U.S. Micro Cap Portfolio ETFDFMC83.92萬0.01%75.58億 USD0.43%US$57.8539+0.07%Avantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Targeted Value ETFDFATU.S. Small Cap Value Portfolio ETF Class SharesDFSVDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
